Latest Posts
About This Stock
More About This Stock
Read
Read
Read
The Risk-On Trade Is Fading, That’s Bad News For Stocks Short-Term
Article By:
Michael J. Kramer
Saturday, July 25, 2020 7:57 PM EDT
The risk-on trade may be in serious jeopardy, and that may be bad for the entire market. When digging deeper into ETF trends, it seems that many that have led the market higher are now beginning to roll over.
4 ETF Areas To Keep Soaring As Coronavirus Cases Rise
Article By:
Zacks Investment Research
Sunday, July 19, 2020 1:45 PM EDT
There are numerous ETFs that investors can consider that take advantage of coronavirus-driven trends such as working and shopping from home and the search for treatments and vaccines.
Biotech Portfolio Review: What To Do Next?
Article By:
Rod Raynovich
Sunday, July 19, 2020 11:53 AM EDT
Your biotech portfolio is probably up at least 10% YTD because the IBB is up ~17% and the XBI up 18.35%. Do you raise cash or go more defensive with the life science positions you own?
In this article: IBB, XBI Also: AZN, BMY, JNJ, MRK, UNH, RHHBY, FBIOX, FSMEX, GILD, FBT, GLD, ABBV, XNCR, TDOC, CRSP
Leadership (Bio-Tech) Breakout; Good Sign For Broad Market
My Simple Forecast:
Looks like $XBI has had a positive growth trend. With middle of the year approaching I believe that the cycle will repeat, thus hitting high points again. The seasonal patterns may be based on the rate of discovery of new technology, so cycles may be of unusual lengths. Nonetheless, looks like $XBI is positively correlated to SP500, and it is leading variable. We can anticipate new highs by beginning Q3.